Hendrik-Tobias Arkenau, MD, PhD

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, executive medical director for Sarah Cannon Research Institute UK, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.

Arkenau emphasizes that gastric cancers are one of the most common cancers worldwide and are related to both the third and fifth most common cancers. TAS-102 has shown good clinical evidence in patients with colorectal cancer and patients with gastric or gastroesophageal cancer.

Videos

Hendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.

Rationale for Using TAS-102 in Patients With Gastric Cancer

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, gives an overview of the JAVELIN trial in gastric cancer. He also discusses the safety profile of avelumab.

JAVELIN Trial Design and Safety Results in Gastric Cancer

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the future of immunotherapy in melanoma.

In the past, the initial successful data of CTLA-4 blockade with ipilimumab resulted in a response rate of about 10%. Today, there are combinations with ipilumumab and evolumab, with response rates in the range of 60%, so there have been very strong results.

Arkenau says it is exciting that the response rates are improving with these combinations and result in prolonged progression-free survival.

Dr. Arkenau Discusses the Future of Immunotherapy in Melanoma

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of a phase I study of AZD4547 in patients with advanced tumors.

AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), has demonstrated promise in patients who have FGFR amplification in their tumor.

Tumor biology is complex, so there may be other alterations that may predict if AZD4547 is working.

Of 21 patients dosed with AZD4547, seven had high FGFR and three of these patients (squamous NSCLC, breast and bladder cancer) had target lesion shrinkage or prolonged (&ge;24 weeks) disease stabilization.

Further work is needed to better understand FGFR signaling.

View more from the 2014 ASCO Annual Meeting

Hendrik-Tobias Arkenau, MD, PhD | Authors

Articles

Rationale for Using TAS-102 in Patients With Gastric Cancer

JAVELIN Trial Design and Safety Results in Gastric Cancer

Dr. Arkenau Discusses the Future of Immunotherapy in Melanoma

AZD4547 and FGFR Amplification in Advanced Solid Tumors